It’s such a pleasure, working with partners in whom you have complete trust. RxCelerate has added value to many of our programs and we have no hesitation recommending them to our friends.

Kevin JohnsonPartner, Medicxi Ventures

Levicept, a biotechnology company developing a novel agent (LEVI-04) for the treatment of osteoarthritis, has been working with RxCelerate for in excess of 3 years.  RxCelerate is a key partner in the development of LEVI-04 and indeed Jill and the team have helped identify and develop bespoke models of osteoarthritis that underpin the translation to man, mechanism(s) of action and subsequently the progression of LEVI-04 to Phase 1clinical trials. 

RxCelerate is more than a CRO but an extension of Levicept’s development team.  RxCelerate adds significant value to our programme by understanding the background science in great depth. Jill and the team are able to provide a service that few CROs are capable of matching.  

I would highly recommend RxCelerate to any pharmaceutical or biotechnology company seeking a contract research organisation that provides exceptionally high quality data, outstanding animal ethical standards, scientific know-how and most importantly a CRO that takes the time to understand the science and consequently helps develop models that meet your scientific and translational goals.

Simon WestbrookCEO, Levicept

RxCelerate was instrumental in the success of XO1. They should be your first port of call for those critical experiments upon which the value and decision-making of your company or programme depend. Jill Reckless is an experimental biologist of the highest order and Jill and her team are wonderfully obsessive about flawless experimental design and execution. They particularly excel in the area of novel model systems where no precedents exist, or where current models are inadequate and need to be re-designed.

Richard MasonCEO, XO1